Designing studies for epigenetic biomarker development in autoimmune rheumatic diseases

3Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

In just a few years, the number of epigenetic studies in autoimmune rheumatic and inflammatory diseases has greatly increased. This is in part due to the need of identifying additional determinants to genetics to explain the pathogenesis and development of these disorders. In this regard, epigenetics provides potential mechanisms that determine gene function, are linked to environmental factors, and could explain a wide range of phenotypic variability among patients with these diseases. Despite the high interest and number of studies describing epigenetic alterations under these conditions and exploring their relationship to various clinical aspects, few of the proposed biomarkers have yet reached clinical practice. The potential of epigenetic markers is high, as these alterations link measurable features with a number of biological traits. In the present article, we present published studies in the field, discuss some frequent limitations in the existing research, and propose a number of considerations that should be taken into account by those starting new projects in the field, with an aim to generate biomarkers that could make it into the clinics.

Cite

CITATION STYLE

APA

Calle-Fabregat, C. D. L., Rodríguez-Ubreva, J., Cañete, J. D., & Ballestar, E. (2022, October 1). Designing studies for epigenetic biomarker development in autoimmune rheumatic diseases. Rheumatology and Immunology Research. Walter de Gruyter GmbH. https://doi.org/10.2478/rir-2022-0018

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free